Core Insights - The article highlights the significant clinical research data presented at the 23rd Asia Pacific Congress of Nephrology (APCN 2025) regarding the core product of the company, NEFECON® (Budesonide Enteric Capsules), which provides evidence-based support for the treatment of IgA nephropathy [1] Group 1: Clinical Research Findings - NEFECON® has shown promising results in multiple clinical studies from top hospitals in China, emphasizing its efficacy and safety in treating IgA nephropathy, a condition affecting approximately 5 million patients in China [1] - The studies presented at the conference indicate a shift in clinical focus from merely improving proteinuria to protecting kidney function for long-term management of IgA nephropathy patients [1] Group 2: Treatment Strategies - Research from Xi'an Jiaotong University First Affiliated Hospital confirms the importance of a full course of targeted therapy for kidney function protection, suggesting a combined approach of "targeted treatment + supportive treatment" for better disease control [2] - A study from Xinjiang Medical University First Affiliated Hospital shows that NEFECON® combined with non-steroidal agents can improve eGFR and reduce proteinuria in patients intolerant to systemic glucocorticoids, with no reported adverse events during the treatment period [2] - Research from Nanchang University First Affiliated Hospital explores the synergistic effects of NEFECON® and hydroxychloroquine, indicating improved outcomes in proteinuria and kidney function across various baseline levels [3] Group 3: Long-term Treatment Benefits - A retrospective real-world study from Macau Kiang Wu Hospital involving 12 patients treated with NEFECON® for 12 months shows significant advantages in proteinuria control and kidney function protection compared to a control group receiving traditional treatment [4] - The NEFECON® group demonstrated a reduction in proteinuria from 1016 mg/d to 114 mg/d, while the control group showed a decrease from 1074 mg/d to 291 mg/d, indicating a more substantial effect [4] - The study supports extending the treatment duration beyond 9 months to achieve sustained kidney protection benefits [5] Group 4: Clinical Value and Market Potential - The findings from APCN 2025 validate NEFECON®'s core value in targeted therapy and enrich its clinical evidence for long-term treatment, providing new therapeutic strategies for IgA nephropathy patients [6] - NEFECON® has been recommended in both the 2025 KDIGO guidelines and the 2025 Chinese guidelines for IgA nephropathy, making it the only drug with dual recognition [7] - The product's sales revenue reached nearly 1 billion yuan from January to September 2025, with annual sales guidance raised to 1.2-1.4 billion yuan, indicating it is one of the fastest-growing chronic disease innovative drugs in recent years [7] - Forecasts suggest that NEFECON® sales could reach 2.4-2.6 billion yuan by 2026, with peak sales potentially hitting 5 billion yuan [7]
云顶新耀耐赋康® 11项中国临床研究亮相APCN 2025